| Document |
Document Title |
|
WO/2018/177301A1 |
The present invention relates to the technical field of medicine, and relates to a 15-idene-14-deoxy-11,12-dehydroandrographolide derivative and a use thereof in anti-fibrosis. Experiments show that this compound can significantly inhibi...
|
|
WO/2018/171817A1 |
Provided is a miticide composition containing two active ingredients, the first whereof comprising at least one compound selected among the compounds A-7, A-8 and A-10, and the second whereof being a group selected among the first to the...
|
|
WO/2018/171589A1 |
The present invention belongs to the field of medicine. Provided are citalopram pamoate, a crystal form thereof, and a preparation method and use of the same. The citalopram pamoate has the structure shown in formula I. The citalopram pa...
|
|
WO/2018/172852A1 |
The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and co...
|
|
WO/2018/172423A1 |
The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p¸ q, L, ׇ, X and m are as defined herein. The compound...
|
|
WO/2018/174293A1 |
An organic electroluminescence element comprising, in the stated order, an anode, an organic layer, a light-emitting layer, and a cathode, the organic layer including the compound represented in formula (20), and the light-emitting layer...
|
|
WO/2018/170932A1 |
The invention provides a method for preparing 1,5-pentanediol via hydrogenolysis of tetrahydrofurfuryl alcohol. The catalyst used in the method is prepared from a nitrogen-containing ligand functionalized organic polymer or inorganic hyb...
|
|
WO/2018/173500A1 |
Provided are: an active ester composition having high curability and exceptional properties such as dielectric properties, heat resistance, and moisture absorption resistance in the cured product; a cured product of the composition; and ...
|
|
WO/2018/175190A1 |
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
|
|
WO/2018/175188A1 |
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma- 2 receptor activity.
|
|
WO/2018/174396A1 |
A method for preparing a furan monomer having a bifunctional hydroxymethyl group (2,5-bis(hydroxymethyl) furan, BHMF), according to various embodiments of the present invention, can comprise the steps of: synthesizing a low-molecular-wei...
|
|
WO/2018/169261A1 |
The present invention provides: a compound capable of enabling high luminous efficiency, a low driving voltage, and an improved lifespan of an element; an organic electric element using the same; and an electronic device thereof.
|
|
WO/2018/168714A1 |
Provided is an oxime ester compound represented by general formula (Iα) or (Iβ). (In the formulae: R1 to R6 and R101 to R108 each independently denote a group represented by general formula (II), a hydrogen atom, a halogen atom, a nitr...
|
|
WO/2018/166031A1 |
A method for preparing furfuryl alcohol by using a hydrogen transfer reaction to catalyze furfural. The method comprises: using low carbon alcohol as a solvent and a hydrogen source, using a zirconium compound as a catalyst, and in the l...
|
|
WO/2018/165501A1 |
The invention provides aryl indolinyl sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORγ activity and/or increasing the amount of IL-17 in a subject, and therapeutic uses of the indolinyl sulfonami...
|
|
WO/2018/164265A1 |
A compound represented by formula (1) provides an organic electroluminescent element that exhibits exceptional luminous efficiency. (In formula (1), R1-R8, R11-R18, R21, R22, L1, L2, L3, Ar1, and Ar2 are as defined in the description.)
|
|
WO/2018/164545A1 |
The present invention provides a novel compound and an organic light emitting element using the same.
|
|
WO/2018/160063A1 |
The invention is directed to the to the electrochemical preparation of 2,5- furandicarboxylic acid (FDCA) from 5-hydroxymethylfurfural (HMF) by electrochemical oxidation, comprising a first oxidation step of oxidizing HMF to 5-hydroxymet...
|
|
WO/2018/157801A1 |
The present invention relates to a cyano group-substituted fused bicyclic derivative, and a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition can be used for inhibiting xanthine oxidase an...
|
|
WO/2018/159650A1 |
The purpose of the present invention is to provide a compound which has a guanidine skeleton and inhibits the protease activity of MALT1 to exhibit a therapeutic effect or prophylactic effect on autoimmune diseases such as psoriasis. The...
|
|
WO/2018/157981A1 |
The present invention relates to triarylamine compounds of general formula (I). The present invention further relates to methods for producing said compounds, oligomers, polymers or dendrimers and to formulations containing said compound...
|
|
WO/2018/157604A1 |
A method for preparing an acidic and hydrophobic Pd/C catalytic material: sequentially carrying out modification by means of chlorosulfonic acid and trimethylchlorosilane, washing and drying, and then obtaining a modified Pd/C catalytic ...
|
|
WO/2018/155340A1 |
The purpose of the present invention is to provide a liquid crystalline compound; a liquid crystal composition containing the compound; and a liquid crystal display element including the composition, the liquid crystalline compound satis...
|
|
WO/2018/152949A1 |
The present invention relates to a method for preparing optically pure (R)-4-n-propyl-dihydrofuran-2(3H)-one, and belongs to the field of chemical synthesis. The method of the present invention uses the steps of alkylation, reduction, cy...
|
|
WO/2018/153727A2 |
The present invention relates to a process for the carbonylation of allyl alcohols at low temperature, low pressure and/or low catalyst load. In an alternative embodiment, an acylation product of allyl alcohol is used for carbonylation. ...
|
|
WO/2018/154519A1 |
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...
|
|
WO/2018/033642A9 |
The present invention relates to a compound of formula (I): wherein L is an optionally substituted heterocyclic group excluding unsubstituted monocyclic pyridine groups; wherein a is 0, 1 or 2; wherein R1 is H or with R2 is a bond; where...
|
|
WO/2018/154493A1 |
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...
|
|
WO/2018/156443A1 |
Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or dis...
|
|
WO/2018/151077A1 |
A compound represented by formula (1). In formula (1), at least one of R1-R10 is a group represented by formula (2). In formula (2), at least one of Ar1 and Ar2 is a group represented by formula (3).
|
|
WO/2018/149850A1 |
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic...
|
|
WO/2018/149856A1 |
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as tocompositions and ophthalmic ...
|
|
WO/2018/150421A1 |
The invention provides efficient cyclization processes of hydroxyalkenoic acids and products produced therefrom. The following reactions are claimed: Formula (I), (II), (V) and (VI).
|
|
WO/2018/149940A1 |
It is described an industrially viable and advantageous process for the preparation of (N- (((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)p
ropionamide, compound having the formula depicted below and generally known as Tasime...
|
|
WO/2018/149853A1 |
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic...
|
|
WO/2018/149991A1 |
The present invention relates to particular sulfonamide derivatives, the pharmaceutically acceptable addition salts thereof, the hydrates thereof and/or the solvates thereof, and also the use thereof as inverse agonists of retinoid-relat...
|
|
WO/2018/149852A1 |
The present invention relates to novel compounds (I) particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthal...
|
|
WO/2018/147094A1 |
A compound represented by formula (I). (In formula (I), each of R1 and R2 independently represents a hydrogen atom or a methyl group; each of X1 and X2 independently represents a group that is represented by one of formula (X1-1) to form...
|
|
WO/2018/146894A1 |
The problem addressed by this invention is to provide an organic electric field light-emitting element having optimal light-emitting characteristics. This problem is addressed by an organic electric field light-emitting element containin...
|
|
WO/2018/146978A1 |
Provided is catalyst (for reduction reaction) which uses a raw material derived from biomass such that 1,4-butanediol or tetrahydrofuran can be obtained with a higher selectivity than is typical. This catalyst is used for a reduction rea...
|
|
WO/2018/146122A1 |
The presently claimed invention is directed to a process for preparing D-glucaro-6,3-lactone from a salt of D-glucaric acid.
|
|
WO/2018/145553A1 |
The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I), compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatricdisorder (e....
|
|
WO/2018/146962A1 |
The purpose of this invention is to provide an organic electric field light-emitting element having optimal light-emitting characteristics. This problem is solved by an organic electric field light-emitting element having a light-emittin...
|
|
WO/2018/147373A1 |
A tetracarboxylic acid dianhydride which is composed of at least one acid dianhydride (A) selected from the group consisting of compounds having an endo/exo type steric structure represented by a specific general formula and enantiomers ...
|
|
WO/2018/141706A1 |
The invention relates to propellane compounds according to defined formula, to the use of said compounds in electronic devices, and to electronic devices containing one or more of the known propellane compounds. The invention also relate...
|
|
WO/2018/141854A1 |
The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity ...
|
|
WO/2018/144910A1 |
The disclosure provides a method of preventing or reducing protein aggregates using combretastatin-A4 (CA4) or an analog thereof. The disclosure also provides methods of reducing the risk, delaying the onset, delaying or slowing the prog...
|
|
WO/2018/138359A1 |
The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of R...
|
|
WO/2018/137959A1 |
The present invention relates to a process for preparing benzylic amides of formula (I) wherein the variables have the meaning as defined in the description, by reductive amidation of a nitrile of formula (II) wherein the variables have ...
|
|
WO/2018/140599A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 ...
|
